3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
13
Carcinoma, Non-Small-Cell Lung
11
Neoplasm Metastasis
7
Brain Neoplasms
7
Rectal Neoplasms
6
Lung Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Prostatic Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Uterine Cervical Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Glioblastoma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Inflammatory Breast Neoplasms
2
Glioma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Adenocarcinoma
2
Vaginal Neoplasms
1
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
decitabine and cedazuridine drug combination
1
apalutamide
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Patient Preference
×
Surgical Procedures, Operative
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts